

FORM PTO-1390 (Modified)  
(REV 11-98)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

205907US0PCT

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

09/830669

INTERNATIONAL APPLICATION NO.  
PCT/FR99/02628INTERNATIONAL FILING DATE  
28 October 1999PRIORITY DATE CLAIMED  
28 October 1998

## TITLE OF INVENTION

PROCESS FOR PRODUCING CHEMICALLY DIVERSIFIED PROTEINS, IN VIVO, BY INCORPORATING  
UNCONVENTIONAL AMINO ACIDS

## APPLICANT(S) FOR DO/EO/US

Philippe MARLIERE, et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
  - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☒ has been transmitted by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
- ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
- ☒ A copy of the International Search Report (PCT/ISA/210).
- ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
- ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
- ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
- ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).


## Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ Certificate of Mailing by Express Mail
20. ☒ Other items or information:

## Request for Consideration of Documents Cited in International Search Report

Notice of Priority

PCT/IB/304

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.53) <b>09/830669</b>		INTERNATIONAL APPLICATION NO. <b>PCT/FR99/02628</b>		ATTORNEY'S DOCKET NUMBER <b>205907US0PCT</b>	
21. The following fees are submitted:.				CALCULATIONS PTO USE ONLY	
<b>BASIC NATIONAL FEE ( 37 CFR 1.492 (a) (1) - (5) ) :</b>					
<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... \$1,000.00					
<input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... \$860.00					
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$710.00					
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$690.00					
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$100.00					
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				<b>\$860.00</b>	
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)). <input type="checkbox"/> 20 <input type="checkbox"/> 30				<b>\$0.00</b>	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	51 - 20 =	31	x \$18.00	<b>\$558.00</b>	
Independent claims	2 - 3 =	0	x \$80.00	<b>\$0.00</b>	
Multiple Dependent Claims (check if applicable).			<input type="checkbox"/>	<b>\$0.00</b>	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$1,418.00</b>	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable).			<input type="checkbox"/>	<b>\$0.00</b>	
<b>SUBTOTAL =</b>				<b>\$1,418.00</b>	
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30				<b>\$0.00</b>	
<b>TOTAL NATIONAL FEE =</b>				<b>\$1,418.00</b>	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).			<input type="checkbox"/>	<b>\$0.00</b>	
<b>TOTAL FEES ENCLOSED =</b>				<b>\$1,418.00</b>	
				Amount to be refunded	\$
				charged	\$
<input checked="" type="checkbox"/> A check in the amount of <b>\$1,418.00</b> to cover the above fees is enclosed.					
<input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed.					
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. <b>15-0030</b> A duplicate copy of this sheet is enclosed.					
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>					
SEND ALL CORRESPONDENCE TO:					
 <b>22850</b>  Surinder Sachar Registration No. 34,423			SIGNATURE  <b>Norman F. Oblon</b> NAME  <b>24,618</b> REGISTRATION NUMBER  <b>4-30-01</b> DATE		

205907US0 PCT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF: :  
PHILLIPPE MARLIERE ET AL : ATTN: NEW APPLICATION DIVISION  
SERIAL NO: NEW US PCT APPLN. :  
(Based on PCT/FR99/02628)  
FILED: HEREWITH :  
FOR: PROCESS FOR PRODUCING :  
CHEMICALLY DIVERSIFIED  
PROTEINS, *IN VIVO*, BY  
INCORPORATING  
UNCONVENTIONAL AMINO  
ACIDS

PRELIMINARY AMENDMENT

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

SIR:

Prior to examination on the merits, please amend the above-identified application as follows:

IN THE CLAIMS

Please amend the claims as shown in the marked-up copy to read as follows:

--3. (Amended) Method according to claim 1, characterized in that step c) for culturing said cells comprises a series of said cells in a culture medium containing the amino acid encoded by said target codon, each of said cultures of the series being prepared as far as obtaining the stationary growth phase and followed by washing of the cells obtained, the number of cultures of the series being sufficient to allow the selection of mutations which increase the suppression of said missense mutation of said mutated gene.

4. (Amended) Method according to claim 1, characterized in that the missense mutation is chosen from missense mutations which spontaneously reverse only at very low frequency, of the order of one organism from at least  $10^{15}$ .

5. (Amended) Method according to claim 1, characterized in that the missense mutation transforms a target codon of a gene encoding a protein required for the growth of said cell, into a codon which, in comparison with the target codon, exhibits a change of at least two bases, preferably three bases.

6. (Amended) Method according to claim 1, characterized in that the target codon encodes an amino acid which has a small steric volume.

7. (Amended) Method according to claim 1, characterized in that the target codon encodes an amphiphilic amino acid.

8. (Amended) Method according to claim 1, characterized in that the target codon encodes an amino acid which has a steric volume smaller than or substantially equal to the steric volume of the amino acid encoded by the missense mutation.

9. (Amended) Method according to claim 5, characterized in that the target codon encodes cysteine.

10. (Amended) Method according to claim 5, characterized in that the amino acid encoded by the missense mutation is valine or isoleucine.

11. (Amended) Method according to claim 1, characterized in that step a) for transforming said cells is carried out using a vector comprising a sequence of said gene encoding a protein required for the growth of said cells, including said missense mutation.

13. (Amended) Method for selecting cells capable of producing a protein the amino acid sequence of which comprises at least one unconventional amino acid, characterized in that it comprises steps a), where appropriate b), and c) of a method according to claim 1, and

selecting the cells capable of growing in step c).

15. (Amended) Method for selecting cells according to claim 13, characterized in that the aminoacyl-tRNA synthetase which recognizes the amino acid encoded by said missense mutation of said selected cells is capable of charging onto one of its associated tRNAs an unconventional amino acid or an amino acid other than said amino acid encoded by said missense mutation.

18. (Amended) Cell obtained using a method according to claim 1.

20. (Amended) Cell according to claim 18, characterized in that it is a prokaryotic or eukaryotic cell.

22. (Amended) Cell according to claim 18, characterized in that it is chosen from the following cells deposited at the CNCM (Collection Nationale de Culture de Microorganismes [National Collection of Microorganism Cultures], Paris, France):

- a) *E. coli* strain deposited at the CNCM under the No. I-2025 on May 25, 1998,
- b) *E. coli* strain deposited at the CNCM under the No. I-2026 on May 25, 1998,
- c) *E. coli* strain deposited at the CNCM under the No. I-2027 on May 25, 1998,
- d) *E. coli* strain deposited at the CNCM under the No. I-2339 on October 26, 1999,
- e) *E. coli* strain deposited at the CNCM under the No. I-2340 on October 26, 1999,

and

- f) *E. coli* strain deposited at the CNCM under the No. I-2341 on October 26, 1999.

23. (Amended) Use of a method according to claim 1 for producing protein the amino acid sequence of which comprises at least one unconventional amino acid.

24. (Amended) Use of a cell according to claim 18 for producing protein the amino acid sequence of which comprises at least one unconventional amino acid.

25. (Amended) Process for producing a protein the amino acid sequence of which comprises at least one unconventional amino acid, characterized in that it comprises the following steps:


- a) where appropriate, selecting a cell by a method according to claim 13;
- b) culturing said cell selected in step a) in a culture medium and under culture conditions which allow the growth of said cell; and
- c) isolating said protein comprising at least one unconventional amino acid from the culture supernatant and/or from the cell pellet obtained in step b).

29. (Amended) Process according to claim 25, characterized in that said cell is auxotrophic for the amino acid encoded by said target codon.

30. (Amended) Process according to claim 25, characterized in that said cell comprises a homologous or heterologous gene of interest the coding sequence of which includes at least one target codon.

32. (Amended) Process according to claim 30, characterized in that the biological activity of the protein encoded by said gene of interest is at least partially conserved after the incorporation of said unconventional amino acid at the level of the target codon of said gene of interest.

33. (Amended) Process according to claim 25, characterized in that the unconventional amino acid is chosen from unconventional amino acids of formula I of configuration L



in which:

R<sub>1</sub> or R<sub>2</sub> represents radicals containing a functional group capable of reacting selectively.

35. (Amended) Process according to claim 25, for protein functionalization.

36. (Amended) Protein purification process, characterized in that it comprises the following steps:

a) incorporating into the amino acid sequence of said protein an unconventional amino acid containing a functional group capable of reacting selectively, using a process according to claim 25;

b) bringing the solution containing the protein obtained in step a) into contact with a support comprising a compound capable of reacting specifically with said functional group and of attaching specifically said protein; and

c) isolating said protein attached to the support.

37. (Amended) Process for attaching a protein to a chemical or biochemical compound, characterized in that it comprises the following steps:

a) incorporating into the amino acid sequence of said protein, by a process according to claim 25, an unconventional amino acid containing a functional group capable of reacting selectively;

b) bringing the protein obtained in step a) into contact with said chemical or biochemical compound comprising a group capable of reacting specifically with said functional group in a medium allowing the reaction.

41. (Amended) Process according to claim 39, characterized in that the chemical or biochemical compound is chosen from compounds capable of modifying the biological activity of the attached protein.

42. (Amended) Process according to claim 39, characterized in that the chemical or biochemical compound is chosen from compounds the biological activity of which can be modified by the attached protein.

43. (Amended) Process according to claim 39, characterized in that the chemical or biochemical compound is chosen from compounds comprising a protein, a polynucleotide, a fatty acid, a sugar or a natural or synthetic polymer.

44. (Amended) Protein obtained using a process according to claim 25.

46. (Amended) Protein complex obtained using a process according to claim 39.

47. (Amended) Use of a protein according to claim 44, as a diagnostic reagent.

48. (Amended) Diagnostic process, characterized in that it uses a protein according to claim 44.

49. (Amended) Diagnostic pack, characterized in that it contains a protein according to claim 44.

50. (Amended) Use of a protein according to claim 44 for preparing a pharmaceutical or cosmetic composition.

51. (Amended) Pharmaceutical or cosmetic composition comprising a protein according to claim 44.--



49. Diagnostic pack, characterized in that it contains a protein according to claim 44 or 45, or a protein complex according to claim 46.

50. Use of a protein according to claim 44 or 45,  
5 of a protein complex according to claim 46 or of a cell according to one of claims 18 to 22 for preparing a pharmaceutical or cosmetic composition.

51. Pharmaceutical or cosmetic composition comprising a protein according to claim 44 or 45, a  
10 protein complex according to claim 46 or a cell according to one of claims 18 to 22.

098065-04001  
FOIE40 6990360

REMARKS

Claims 1-51 are active in the present application. The claims are amended to remove multiple dependencies. No new matter is added. An action on the merits and allowance of the claims is solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.



Norman F. Oblon  
Attorney of Record  
Registration No. 24,618

Daniel J. Pereira, Ph.D.  
Registration No. 45,518



**22850**

(703) 413-3000  
Fax #: (703) 413-2220  
NFO:DJP\cct

I:\user\DJPER\205907US-pr.wpd

**Marked-Up Copy**

Serial No: \_\_\_\_\_

Amendment Filed on: \_\_\_\_\_

IN THE CLAIMS

Please amend the claims as follows:

--3. (Amended) Method according to [either of claims 1 and 2] claim 1, characterized in that step c) for culturing said cells comprises a series of said cells in a culture medium containing the amino acid encoded by said target codon, each of said cultures of the series being prepared as far as obtaining the stationary growth phase and followed by washing of the cells obtained, the number of cultures of the series being sufficient to allow the selection of mutations which increase the suppression of said missense mutation of said mutated gene.

4. (Amended) Method according to [one of claims 1 to 3] claim 1, characterized in that the missense mutation is chosen from missense mutations which spontaneously reverse only at very low frequency, of the order of one organism from at least  $10^{15}$ .

5. (Amended) Method according to [one of claims 1 to 4] claim 1, characterized in that the missense mutation transforms a target codon of a gene encoding a protein required for the growth of said cell, into a codon which, in comparison with the target codon, exhibits a change of at least two bases, preferably three bases.

6. (Amended) Method according to [one of claims 1 to 5] claim 1, characterized in that the target codon encodes an amino acid which has a small steric volume.

7. (Amended) Method according to [one of claims 1 to 6], claim 1, characterized in

that the target codon encodes an amphiphilic amino acid.

8. (Amended) Method according to [one of claims 1 to 7] claim 1, characterized in that the target codon encodes an amino acid which has a steric volume smaller than or substantially equal to the steric volume of the amino acid encoded by the missense mutation.

9. (Amended) Method according to [one of claims 5 to 8] claim 5, characterized in that the target codon encodes cysteine.

10. (Amended) Method according to [one of claims 5 to 9] claim 5, characterized in that the amino acid encoded by the missense mutation is valine or isoleucine.

11. (Amended) Method according to [one of claims 1 to 10] claim 1, characterized in that step a) for transforming said cells is carried out using a vector comprising a sequence of said gene encoding a protein required for the growth of said cells, including said missense mutation.

13. (Amended) Method for selecting cells capable of producing a protein the amino acid sequence of which comprises at least one unconventional amino acid, characterized in that it comprises steps a), where appropriate b), and c) of a method according to [one of claims 1 to 12] claim 1, and selecting the cells capable of growing in step c).

15. (Amended) Method for selecting cells according to [either of claims 13 and 14] claim 13, characterized in that the aminoacyl-tRNA synthetase which recognizes the amino acid encoded by said missense mutation of said selected cells is capable of charging onto one of its associated tRNAs an unconventional amino acid or an amino acid other than said amino acid encoded by said missense mutation.

18. (Amended) Cell obtained using a method according to [one of claims 1 to 17] claim 1.

20. (Amended) Cell according to claim 18 [or 19], characterized in that it is a

prokaryotic or eukaryotic cell.

22. (Amended) Cell according to [one of claims 18 to 21] claim 18, characterized in that it is chosen from the following cells deposited at the CNCM (Collection Nationale de Culture de Microorganismes [National Collection of Microorganism Cultures], Paris, France):

- a) *E. coli* strain deposited at the CNCM under the No. I-2025 on May 25, 1998,
- b) *E. coli* strain deposited at the CNCM under the No. I-2026 on May 25, 1998,
- c) *E. coli* strain deposited at the CNCM under the No. I-2027 on May 25, 1998,
- d) *E. coli* strain deposited at the CNCM under the No. I-2339 on October 26, 1999,
- e) *E. coli* strain deposited at the CNCM under the No. I-2340 on October 26, 1999,

and

- f) *E. coli* strain deposited at the CNCM under the No. I-2341 on October 26, 1999.

23. (Amended) Use of a method according to [one of claims 1 to 17] claim 1 for producing protein the amino acid sequence of which comprises at least one unconventional amino acid.

24. (Amended) Use of a cell according to [one of claims 18 to 22] claim 18 for producing protein the amino acid sequence of which comprises at least one unconventional amino acid.

25. (Amended) Process for producing a protein the amino acid sequence of which comprises at least one unconventional amino acid, characterized in that it comprises the following steps:

- a) where appropriate, selecting a cell by a method according to [one of claims 13 to 17] claim 13;
- b) culturing said cell selected in step a) [or a cell according to one of claims 18 to 22]

in a culture medium and under culture conditions which allow the growth of said cell; and


c) isolating said protein comprising at least one unconventional amino acid from the culture supernatant and/or from the cell pellet obtained in step b).

29. (Amended) Process according to [one of claims 25 to 28] claim 25, characterized in that said cell is auxotrophic for the amino acid encoded by said target codon.

30. (Amended) Process according to [one of claims 25 to 29] claim 25, characterized in that said cell comprises a homologous or heterologous gene of interest the coding sequence of which includes at least one target codon.

32. (Amended) Process according to claim 30 [or 31], characterized in that the biological activity of the protein encoded by said gene of interest is at least partially conserved after the incorporation of said unconventional amino acid at the level of the target codon of said gene of interest.

33. (Amended) Process according to [one of claims 25 to 32] claim 25, characterized in that the unconventional amino acid is chosen from unconventional amino acids of formula I of configuration L



in which:

$\text{R}_1$  or  $\text{R}_2$  represents radicals containing a functional group capable of reacting

selectively.

35. (Amended) Process according to [one of claims 25 to 34] claim 25, for protein functionalization.

36. (Amended) Protein purification process, characterized in that it comprises the following steps:

a) incorporating into the amino acid sequence of said protein an unconventional amino acid containing a functional group capable of reacting selectively, using a process according to [one of claims 25 to 35] claim 25;

b) bringing the solution containing the protein obtained in step a) into contact with a support comprising a compound capable of reacting specifically with said functional group and of attaching specifically said protein; and

c) isolating said protein attached to the support.

37. (Amended) Process for attaching a protein to a chemical or biochemical compound, characterized in that it comprises the following steps:

a) incorporating into the amino acid sequence of said protein, by a process according to [one of claims 25 to 35] claim 25, an unconventional amino acid containing a functional group capable of reacting selectively;

b) bringing the protein obtained in step a) into contact with said chemical or biochemical compound comprising a group capable of reacting specifically with said functional group in a medium allowing the reaction.

41. (Amended) Process according to claim 39 [or 40], characterized in that the chemical or biochemical compound is chosen from compounds capable of modifying the biological activity of the attached protein.

42. (Amended) Process according to claim 39 [or 40], characterized in that the

chemical or biochemical compound is chosen from compounds the biological activity of which can be modified by the attached protein.

43. (Amended) Process according to [one of claims 39 to 42] claim 39, characterized in that the chemical or biochemical compound is chosen from compounds comprising a protein, a polynucleotide, a fatty acid, a sugar or a natural or synthetic polymer.

44. (Amended) Protein obtained using a process according to [one of claims 25 to 36] claim 25.

46. (Amended) Protein complex obtained using a process according to [one of claims 39 to 43] claim 39.

47. (Amended) Use of a protein according to claim 44 [or 45, or of a protein complex according to claim 46], as a diagnostic reagent.

48. (Amended) Diagnostic process, characterized in that it uses a protein according to claim 44 [or 45, or a protein complex according to claim 46].

49. (Amended) Diagnostic pack, characterized in that it contains a protein according to claim 44 [or 45, or a protein complex according to claim 46].

50. (Amended) Use of a protein according to claim 44 [or 45, of a protein complex according to claim 46 or of a cell according to one of claims 18 to 22] for preparing a pharmaceutical or cosmetic composition.

51. (Amended) Pharmaceutical or cosmetic composition comprising a protein according to claim 44 [or 45, a protein complex according to claim 46 or a cell according to one of claims 18 to 22].--



PROCESS FOR PRODUCING CHEMICALLY DIVERSIFIED  
PROTEINS, IN VIVO, BY INCORPORATING UNCONVENTIONAL  
AMINO ACIDS

5 The present invention relates to methods which  
allow prokaryotic or eukaryotic cells to acquire the  
capacity to produce proteins the amino acid sequences  
of which comprise at least one unconventional amino  
acid, to methods for selecting said cells, to methods  
for producing and for purifying said proteins, and also  
10 to the cells and proteins obtained using the methods  
and processes according to the invention. The invention  
also comprises the uses of said cells and proteins in  
various domains, such as the therapeutic, cosmetic or  
diagnostic domain or the domain of biosynthesis, or the  
15 biodegradation of organic compounds.

An increasing number of proteins which are  
mass-produced using recombinant organisms are employed  
as catalysts in the chemical industry or as therapeutic  
agents. The search for novel proteins with diversified  
20 functions is the subject of intense activity, either by  
screening the proteins of extremophilic organisms, or  
by creating protein variants by mutagenesis and  
screening. However, the chemical variability of the  
proteins which can be produced in living organisms  
25 remains limited by the invariance of the genetic code,  
i.e. restricted to combinations of a canonical set of  
20 amino acids. If descendance of natural species could  
be progressively remodeled in the laboratory so as to  
adopt various genetic codes, protein evolution could be  
30 redirected and artificial sources of biodiversity  
thereby established.

Experimental deviation of the genetic code is  
the only path which would make it possible to overcome  
this limitation. An alternative genetic code might  
35 specify a smaller or larger set of amino acids, a set  
substituted with noncanonical monomers or a set of  
canonical amino acids among which the codons are  
redistributed. The specification of additional amino

09/830669 "043001"

acids in living lines would lend itself to many uses, the most generic of which would be the establishment of artificial biodiversity.

The permanent or transient incorporation of a single additional amino acid, carrying a chemical motif which could react without modifying the conventional amino acids, would be sufficient to establish novel protein functionalization methods. This is precisely the subject of the present invention.

A subject of the invention is a method which allows cells to acquire the capacity to produce a protein the amino acid sequence of which comprises at least one unconventional amino acid, characterized in that it comprises the following steps:

- a) transforming said cells by at least one introduction of a missense mutation in a target codon of a gene encoding a protein required for the growth of said cells, said protein synthesized from the gene thus mutated no longer being functional;
- b) where appropriate, culturing the cells obtained in step a) in a culture medium containing the nutrient required by the loss of functionality of said protein thus mutated; and
- c) culturing the cells obtained in step a) or b) in a culture medium containing the amino acid encoded by said target codon.

In the present description, the term "protein" will be intended to also refer to peptides or polypeptides, and also to the corresponding glycoproteins when said proteins are glycosylated.

In the present description, the term "unconventional amino acid" will be intended to also refer to any amino acid other than the amino acids incorporated by ribosomes during the biosynthesis of proteins synthesized by prokaryotic or eukaryotic, unicellular or multicellular organisms, and also to any amino acid incorporated in place of the amino acid which should normally be incorporated at this site with regard to the translated nucleic acid sequence.

In the present description, the term "missense mutation" will be intended to also refer to a mutation which transforms a codon which represents an amino acid into a codon which encodes another amino acid, the latter, where appropriate, being unable to replace the amino acid of origin so as to give a functional protein, in the protein at the site of the amino acid residue of origin.

In the present description, the expression "protein required for the growth of cells" will be intended to also refer to a protein which, when it is synthesized by cells in a functional manner, allows said cells to grow under given culture conditions and which, when it is synthesized by cells in a nonfunctional manner, requires the introduction of an additional nutrient into said given culture medium in order to allow said cells to grow. Such nonfunctional proteins can, for example, be synthesized by cells subsequent to conditional mutations such as a photosensitive-type mutation.

In order to illustrate with an example, but without being limited thereto, mention may be made in particular of the thymidylate synthase protein of *E. coli*, which has a catalytic site occupied by cysteine at position 146 of its amino acid sequence, and the corresponding mutations of the gene (*thyA*) of which cause a nutritional requirement for thymine or thymidine, no other amino acid being able to replace cysteine at this site.

In the present description, the term "target codon" will be intended to refer to the three-nucleotide-base codon transformed by the missense mutation.

The invention also comprises a method according to the invention, characterized in that the culture medium of step c) does not contain the nutrient required by the loss of functionality of said mutated protein.

According to the invention, step c) for culturing said cells can comprise a series of cultures of said cells in a culture medium containing the amino acid encoded by said target codon, each of said  
5 cultures of the series being prepared as far as obtaining the stationary growth phase and followed by washing of the cells obtained, the number of cultures of the series being sufficient to allow the selection of mutations which increase the suppression of said  
10 missense mutation of said mutated gene, and the propagation of the allele corresponding to said mutated gene.

The invention also relates to a method according to the invention, characterized in that the  
15 missense mutation is chosen from missense mutations which spontaneously reverse only at very low frequency, of the order of one organism from at least  $10^{15}$ .

Preferably, the missense mutation will be chosen from missense mutations which transform a target  
20 codon of a gene encoding a protein required for the growth of said cell, into a codon which, in comparison with the target codon, exhibits a change of at least two bases, more preferably three bases.

Preference is also given to the methods  
25 according to the invention, characterized in that the target codon encodes an amino acid which has a small steric volume and/or which is amphiphilic and/or which has a steric volume smaller than or substantially equal to the steric volume of the amino acid encoded by the  
30 missense mutation.

Among the target codons, preference is in particular given to target codons encoding cysteine and missense mutations chosen from missense mutations which transform a target codon into a codon encoding valine  
35 or isoleucine.

The invention also relates to a method according to the invention, characterized in that step a) for transforming said cells is carried out using a vector comprising a sequence of said gene

09830669-043001

encoding a protein required for the growth of said cells, including said missense mutation, in particular using a plasmid vector.

Such vectors will be prepared according to methods commonly used by those skilled in the art, and the clones resulting therefrom can be introduced into said cells by usual methods of genetic recombination, such as for example lipofection, electroporation or heat-shock.

10 In another aspect, a subject of the invention is a method for selecting cells capable of producing a protein the amino acid sequence of which comprises at least one unconventional amino acid, characterized in that it comprises steps a), where appropriate b), and  
15 c) of a method according to the invention, and selecting the cells capable of growing in step c).

Preferably, the method for selecting cells according to the invention will also comprise a step d) for culturing the cells in step c) in a culture medium  
20 containing said amino acid encoded by said target codon, the concentration of said amino acid possibly being at a concentration higher than the concentration of said amino acid used in step c), and choosing the cells sensitive to the concentration of said amino acid  
25 used in step d).

The expression "cell sensitive to a chemical or biochemical compound or to a given concentration of said compound" is intended to refer to a cell the growth of which is partially or totally inhibited when  
30 it is cultured in a culture medium containing said chemical or biochemical compound or said concentration of said compound.

The invention also comprises a method for selecting cells according to the invention,  
35 characterized in that the aminoacyl-tRNA synthetase which recognizes the amino acid encoded by said missense mutation of said selected cells is capable of charging onto one of its associated tRNAs an

09330669-043001

unconventional amino acid or an amino acid other than said amino acid encoded by said missense mutation.

In the present description, the term "associated tRNA" is intended to refer to a tRNA which is recognized by the aminoacyl-tRNA synthetase which recognizes an amino acid, and which can transfer said amino acid.

The invention also comprises a method for selecting mutant cells according to the invention, characterized in that the nucleic acid sequence of the gene encoding said aminoacyl-tRNA synthetase includes at least one mutation compared with the sequence of the corresponding wild-type gene, said mutation not having been introduced by a technique of genetic recombination.

According to another aspect, a subject of the invention is the prokaryotic or eukaryotic cells obtained using a method according to the invention.

Among the cells which can be used for these purposes, mention may of course be made of bacterial cells, such as *E. coli*, but also yeast cells, as well as animal cells, in particular mammalian cell cultures, such as in particular Chinese hamster ovary (CHO) cells, and also insect cells.

The invention also relates to the isolated prokaryotic or eukaryotic cells capable of producing a protein the amino acid sequence of which comprises at least one unconventional amino acid, characterized in that they comprise an aminoacyl-tRNA synthetase which recognizes a given amino acid and which is capable of charging onto one of its associated tRNAs an unconventional amino acid or an amino acid other than said given amino acid, and in that the nucleic acid sequence of the gene encoding said aminoacyl-tRNA synthetase includes at least one mutation compared with the sequence of the corresponding wild-type gene, said mutation not having been introduced by a technique of genetic recombination.

Thus, the invention relates to a method for selecting cells, based on the constitution, by the cell, of a metabolic pathway required for its growth, making it possible to obtain cells capable of producing  
5 a noncanonical acyl-tRNA capable of charging an unconventional amino acid.

Among the cells according to the invention, preference is given to bacterial cells characterized in that they are chosen from the following cells deposited  
10 at the CNCM (Collection Nationale de Culture de Microorganismes [National Collection of Microorganism Cultures], Paris, France):

- a) *E. coli* strain deposited at the CNCM under the No. I-2025 on May 25, 1998,
- 15 b) *E. coli* strain deposited at the CNCM under the No. I-2026 on May 25, 1998,
- c) *E. coli* strain deposited at the CNCM under the No. I-2027 on May 25, 1998,
- d) *E. coli* strain deposited at the CNCM under the  
20 No. I-2339 on October 26, 1999,
- e) *E. coli* strain deposited at the CNCM under the No. I-2340 on October 26, 1999, and
- f) *E. coli* strain deposited at the CNCM under the No. I-2341 on October 26, 1999.

25 The *E. coli* strain K12, deposited at the CNCM under the No. I-2025 and identified under the reference  $\beta$ 5366, is a descendent of the strain MG1655 (wt *E. coli* K12), which includes the following characteristics:

- deletion at the *thyA* locus and replacement  
30 with an erythromycin resistance gene,
- carries a plasmid pTZ18 (col E1 replicon, *bla*<sup>+</sup>) with the Cys146GUA allele of thymidylate synthase.

The *E. coli* strain K12, deposited at the CNCM  
35 under the No. I-2026 and identified under the reference  $\beta$ 8144, is a descendant of the strain MG1655 (wt *E. coli* K12), which includes the following characteristics:

- deletion at the *thyA* locus and replacement with an erythromycin resistance gene,

09830669-043001

- carries a plasmid pTZ18 (col E1 replicon, bla<sup>+</sup>) with the Cys146GUA allele of thymidylate synthase.

5 The *E. coli* strain K12, deposited at the CNCM under the No. I-2027 and identified under the reference  $\beta$ 8146, is a descendant of the strain MG1655 5WT *E. coli* K12), which includes the following characteristics:

- deletion at the thyA locus and replacement with an erythromycin resistance gene,

10 - carries a plasmid pTZ18 (col E1 replicon, bla<sup>+</sup>) with the Cys146GUA allele of thymidylate synthase.

15 The *E. coli* strain K12, deposited at the CNCM under the No. I-2339 and identified under the reference  $\beta$ 5479, is a descendant of the strain MG1655 (wt *E. coli* K12), which includes the following characteristics:

- deletion at the thyA locus and replacement with an erythromycin resistance gene,

20 - deletion at the nrdD locus and replacement with a kanamycin resistance gene,

- carries the R223H allele of the valS gene,

- carries a plasmid pTZ18 (col E1 replicon, bla<sup>+</sup>) with the Cys146GUA allele of thymidylate synthase.

25 The *E. coli* strain K12, deposited at the CNCM under the No. I-2340 and identified under the reference  $\beta$ 5485, is a descendant of the strain MG1655 (wt *E. coli* K12), which includes the following characteristics:

30 - deletion at the thyA locus and replacement with an erythromycin resistance gene,

- deletion at the nrdD locus and replacement with a kanamycin resistance gene,

- carries the Val 276 Ala chromosomal allele of the valS gene,

35 - carries a plasmid pTZ18 (col E1 replicon, bla<sup>+</sup>) with the Cys146GUA allele of thymidylate synthase.

The *E. coli* strain K12, deposited at the CNCM under the No. I-2341 and identified under the reference

09830669-043001



β5486, is a descendant of the strain MG1655 (wt *E. coli* K12), which includes the following characteristics:

- deletion at the *thyA* locus and replacement with an erythromycin resistance gene,

5       - deletion at the *nrdD* locus and replacement with a kanamycin resistance gene,

- carries the Asp 230 Asn chromosomal allele of the *valS* gene,

10       - carries a plasmid pTZ18 (col E1 replicon, bla<sup>+</sup>) with the Cys146GUA allele of thymidylate synthase.

15       The invention also comprises the use of a method or of a cell according to the invention for producing protein, in particular recombinant protein, the amino acid sequence of which comprises at least one unconventional amino acid.

20       In another aspect, the invention relates to a process for producing a protein the amino acid sequence of which comprises at least one unconventional amino acid, characterized in that it comprises the following steps:

- a) where appropriate, selecting a cell by a method according to the invention;
- 25       b) culturing said cell selected in step a) or a cell according to the invention in a culture medium and under culture conditions which allow the growth of said cell; and
- 30       c) isolating said protein comprising at least one unconventional amino acid from the culture supernatant and/or from the cell pellet obtained in step b).

35       Among the proteins which can be produced by a process according to the invention, mention may be made, but without being limited thereto, of proteins which, through the incorporation of at least one unconventional amino acid, make it possible to obtain a desired activity which a protein the sequence of which includes only conventional amino acids does not make it possible to obtain. The term "activity" is intended to

refer, in general, to any activity such as a physiological or biological activity, even partial, relating to unicellular or multicellular organisms, such as for example a structural or biochemical activity, for example an enzymatic or antigenic activity, an activity of antibody type, or an activity which modulates, regulates or inhibits biological activity, or such that it allows the implementation thereof in a process for biosynthesizing or for biodegrading chemical or biochemical compounds.

Among the proteins which can be produced by a process according to the invention, mention may also be made of proteins for which the incorporation of at least one unconventional amino acid is carried out such that there results therefrom no substantial modification of the biological activity of the corresponding unmodified protein. Besides the conserved biological activity of the corresponding unmodified protein, these proteins according to the invention will have an unconventional amino acid with specific properties which may be advantageously exploited.

Among the specific properties conferred by the presence of an unconventional amino acid, mention may be made in particular of the properties linked to the presence of a functional group on said unconventional amino acid, capable of reacting easily and specifically with a chemical or biochemical compound under conditions which make it possible not to modify the activity of the protein or which avoid modifying the conventional amino acids.

The presence of this specific functional group may advantageously be used, for example, for:

- (i) purifying any protein, in particular any recombinant protein, which incorporates said unconventional amino acid;
- (ii) coupling such a protein to a solid support;
- (iii) coupling to such a protein molecules capable of being detected, such as spectroscopic probes of varied nature;

(iv) coupling to such a protein lipophilic or hydrophilic polymers which allow the solubilization thereof in solvents or which allow masking against recognition by antibodies;

5 (v) coupling such a protein to a polynucleotide;

(vi) coupling such a protein to a chemical or biochemical compound the presence of which makes it possible to increase, to decrease, to modify, to regulate or to target the biological activity of said protein, or to modify the bioavailability thereof as a compound for therapeutic use; or

10 (vii) permanently attaching to such a protein a coenzyme which otherwise would diffuse in solution.

According to the present invention, the  
15 incorporation of at least one unconventional amino acid may relate to amino acids responsible for specificity or for the activity, or responsible for the structural conformation, for the charge, for the hydrophobicity or for the multimerization capacity of the corresponding  
20 unmodified protein. Thus, proteins of equivalent, increased or decreased activity, or of specificity which is equivalent, more restricted or broader than the corresponding unmodified protein containing conventional amino acids may be created.

25 The term "unmodified protein" is intended to refer to the wild-type or recombinant protein which consists of conventional amino acids, and from which is derived the protein comprising the unconventional amino acid.

30 Preferably, the production process according to the invention is characterized in that said culture medium of step b) which allows the growth of said cell contains said unconventional amino acid or a precursor thereof.

35 According to one particular embodiment, a production process according to the invention is characterized in that said unconventional amino acid is synthesized by said cell, the synthesis of said

09830669 043001

unconventional amino acid possibly being increased by genetic modification of said cell.

5 The invention also relates to a process for producing a protein the amino acid sequence of which comprises at least one unconventional amino acid according to the invention, characterized in that said cell is auxotrophic for the amino acid encoded by said target codon.

10 Also included in the present invention are the processes according to the invention, characterized in that said cell comprises a homologous or heterologous gene of interest the coding sequence of which includes at least one target codon.

15 In general, the gene of interest will encode a messenger RNA which will then be translated into a protein of interest.

20 The gene of interest can be isolated by any conventional technique, such as cloning or PCR (Polymerase Chain Reaction), or chemically synthesized. It can be of genomic (possessing one or more introns) or complementary DNA (cDNA) type. The protein of interest can consist of a mature protein, a precursor, and in particular a precursor intended to be secreted and comprising a signal peptide, a truncated protein, a chimeric protein originating from the fusion of sequences of diverse origins, or a mutated protein having improved and/or modified biological properties.

25 In general, the homologous or heterologous gene of interest may be chosen from genes encoding any protein which can be used as a therapeutic or cosmetic compound, or as a diagnostic reagent or as a compound which can be used in a biosynthesis or biodegradation process.

30 By way of examples, mention may be made of genes of interest encoding the following proteins of interest:

- cytokines or lymphokines ( $\alpha$ -,  $\beta$ - and  $\gamma$ -interferons, interleukins, and in particular IL-2, IL-6, IL-10 or

09330669 043001

IL-12, tumor necrosis factors (TNFs), colony stimulating factors (GM-CSF, C-CSF, M-CSF, etc.);

- cell or nuclear receptors, in particular those recognized by pathogenic organisms (viruses, bacteria or parasites), or the ligands thereof;

- proteins involved in a genetic disease (factor VII, factor VIII, factor IX, dystrophin or minidystrophin, insulin, CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) protein, growth hormones (hGH));

- enzymes (urease, renin, thrombin, etc.) or any enzymes involved in the metabolism or biosynthesis of proteins, of lipids, of nucleic acids, of sugars, of amino acids, of fatty acids or of nucleotides;

- enzyme inhibitors ( $\alpha$ -1-antitrypsin, antithrombin III, viral protease inhibitors, etc.);

- compounds with an antitumor effect, capable of inhibiting at least partially the initiation or progression of tumors or cancers (antibodies, inhibitors acting on cell division or on transduction signals, tumors suppressor gene expression products, for example p53 or Rb, proteins which stimulate the immune system, etc.);

- class I or II major histocompatibility complex proteins, or regulatory proteins which act on the expression of the corresponding genes

- proteins capable of inhibiting a viral, bacterial or parasitic infection or the development thereof (antigenic proteins having immunogenic properties, antigenic epitopes, antibodies, etc.);

- toxins such as ricin, cholera, diphtheria, etc. toxins, or immunotoxins;

- markers ( $\beta$ -galactosidase, peroxidase, etc.); and


- luciferase, GFP (green fluorescent protein), etc.

The invention also comprises a process for producing a protein according to the invention, characterized in that the culture medium of step b) also comprises the compounds required for inducing the synthesis of the protein encoded by said gene of

interest. These compounds are known to those skilled in the art and depend, in particular, on the cell and on the homologous or heterologous gene selected.

5 The invention also relates to a process according to the invention, characterized in that the biological activity of the protein encoded by said gene of interest is at least partially conserved after the incorporation of said unconventional amino acid at the level of the target codon of said gene of interest.

10 The invention also relates to a process according to the invention, characterized in that the unconventional amino acid is chosen from unconventional amino acids of formula I and of configuration L



(I)

in which:

15 R<sub>1</sub> or R<sub>2</sub> represents radicals containing a functional group capable of reacting selectively, preferably chosen from aldehyde, ketone, ethenyl, ethynyl and nitrile groups.

20 Among these groups, preference is given particularly to the oxo (aldehyde or ketone) group with selective reactivity which would facilitate the chemical functionalization of the proteins. Other simple groups, such as the ethynyl group, would also lend themselves to selective reactions. A vast collection of experiments conducted with the aid of systems of acellular (ex vivo) translation and of  
25 acyl-tRNAs synthesized in vitro has demonstrated that a large variety of acyl groups can be transferred on the ribosome in response to a codon read by the tRNA. Briefly, lateral modifications of amino acids all appear to be compatible with translation (to date, no  
30

amino acid having a side chain which would be bulky enough to block translation has been found); substitutions of the amino motif to an alkylamino, to a hydroxyl and to a hydrazino motif are compatible with ribosome-catalyzed transpeptidation chemistry (Bain et al. 1991) (it is known that the ribosome can form polyesters in addition to conventional polyamides); the substitution of the alpha hydrogen of the  $H_2NCH(R)-COOH$  motif with an alkyl (methyl) group, or the inversion of configuration at the alpha carbon (D-amino acids) is not, on the other hand, accepted by the ribosome.

A subject of the invention is also a process according to the invention, for protein functionalization.

The invention also relates to a protein purification process, characterized in that it comprises the following steps:

- a) incorporating into the amino acid sequence of said protein an unconventional amino acid containing a functional group capable of reacting selectively, using a process according to the invention;
- b) bringing the solution containing the protein obtained in step a) into contact with a support comprising a compound capable of reacting specifically with said functional group and of attaching specifically said protein; and
- c) isolating said protein attached to the support.

The processes for purifying protein, which may be natural or recombinant, conventionally used by those skilled in the art generally employ methods used individually or in combination, such as fractionation, chromatography methods, immunoaffinity techniques using specific mono- or polyclonal antibodies, etc. These methods are sometimes long and tedious and do not always make it possible to obtain the specific activity, the level and the yield of purification desired. The presence of a specific functional group on the protein to be purified, which group is capable of

reacting selectively with the purification support without modifying the activity of the protein, would greatly facilitate the purification of protein required for the use thereof.

5           The invention also relates to a process for attaching a protein to a chemical or biochemical compound, characterized in that it comprises the following steps:

- 10           a) incorporating into the amino acid sequence of said protein, by a process according to the invention, an unconventional amino acid containing a functional group capable of reacting selectively;
- 15           b) bringing the protein obtained in step a) into contact with said chemical or biochemical compound comprising a group capable of reacting specifically with said functional group in a medium allowing the reaction.

20           Preferably, the attachment of a protein to a chemical or biochemical compound is an attachment by covalent bonding.

25           The chemical or biochemical compounds which can be used in said attachment process according to the invention may be chosen from all compounds capable of reacting with the functional group of the incorporated unconventional amino acid.

30           In the present description, the term "protein complex" is intended to refer to the product obtained in step b) of the process described above, comprising a protein according to the invention attached to a chemical or biochemical compound.

35           The invention also comprises a process according to the invention, characterized in that said chemical or biochemical compound is, itself, attached to a solid support or is a constituent compound of a solid support.

          The invention also relates to a process according to the invention, for preparing a protein complex.

09330669-043001



Preferably, the invention comprises the processes of the invention, characterized in that said attached protein or said chemical or biochemical compound is chosen from therapeutic, cosmetic or diagnostic compounds.

Said attached protein will be chosen, in particular, from proteins the amino acid sequence of which comprises an unconventional amino acid according to a process of the invention, and for which the corresponding wild-type or recombinant unmodified protein is chosen from proteins which can be used as therapeutic or cosmetic compounds or as diagnostic reagents.

Preferably, the processes according to the invention are characterized in that the chemical or biochemical compound is chosen from compounds capable of modifying the biological activity of the attached protein.

The expression "compounds capable of modifying the biological activity of another compound" is intended to refer to a compound capable of increasing, of decreasing or of regulating the biological activity of said other compound.

The invention also comprises a process according to the invention, characterized in that the chemical or biochemical compound is chosen from compounds the biological activity of which can be modified by the attached protein.

The invention also comprises a process according to the invention, characterized in that the chemical or biochemical compound is chosen from compounds comprising a protein, a polynucleotide, a fatty acid, a sugar or a natural or synthetic polymer.

According to another aspect, a subject of the invention is the proteins, in particular the recombinant proteins, and the protein complexes obtained by a process according to the invention.

The invention also comprises a method for selecting compounds capable of binding to a protein

05830669 043001

according to the invention or capable of binding to the chemical or biochemical compound of the protein complex according to the invention. Among these methods, mention may be made, as an example, of a method  
5 characterized in that it comprises the following steps:

a) bringing said compound which may be selected into contact with the protein or the protein complex according to the invention, said protein or protein complex possibly being in particular attached to a  
10 solid support;

b) determining the capacity of said compound to bind with the protein or the protein complex according to the invention.

The compounds which may be selected can be  
15 organic compounds, such as proteins or carbohydrates, or any other already known organic or inorganic compounds, or novel organic compounds developed using molecular modeling techniques and obtained by chemical or biochemical synthesis, these techniques being known  
20 to those skilled in the art.

The cells according to the invention may also advantageously serve as a model, and be used in processes for studying, identifying and/or selecting proteins according to the invention or compounds which  
25 may possess a desired activity.

The invention also relates to the use of a protein or of a protein complex according to the invention as a diagnostic reagent, and also to the diagnostic processes, in particular for specifically  
30 detecting, identifying, locating and/or assaying polypeptides or polynucleotides, using a protein or a protein complex according to the invention.

Proteins having incorporated at least one unconventional amino acid and having partially or  
35 totally conserved the initial activity of the corresponding unmodified wild-type or recombinant proteins, such as antibodies, antigens, enzymes or the biologically active fragments thereof known to be used

0930669 043004

in diagnostic processes are, specifically, included in the proteins according to the invention.

Similarly, protein complexes formed from a protein according to the invention and a chemical or biochemical compound, such as complexes comprising an antibody, an antigen or an oligonucleotide probe coupled to an enzyme, to a substrate or to a molecule capable of being detected, are included in the protein complexes according to the invention.

Among the diagnostic processes according to the invention, mention may be made, for example, of the processes comprising the following steps:

a) bringing the biological sample which may contain the compound sought into contact with a protein or a protein complex according to the invention, said protein or protein complex possibly being in particular attached to a solid support; and

b) revealing, identifying, locating and/or assaying the complex formed between the compound sought and a protein or a protein complex according to the invention.

Those skilled in the art will be able to adapt the known standard diagnostic processes to the proteins or the protein complexes according to the invention.

The specific techniques and reagents which allow the complex formed to be revealed, identified, located and/or assayed, and which may be used in the processes of the invention, are also well known to those skilled in the art and are, for example, the ELISA, RIA, immunofluorescence or PCR techniques, or other techniques for amplifying a target nucleic acid which are known to those skilled in the art.

The invention also relates to a diagnostic kit or pack, in particular for specifically detecting, identifying, locating and/or assaying proteins or polynucleotides, characterized in that it contains a protein or a protein complex according to the invention.

The invention also relates to the use of a protein, of a protein complex or of a cell according to the invention, for preparing a pharmaceutical or cosmetic composition.

5 Finally, a subject of the invention is a pharmaceutical or cosmetic composition comprising a protein, a protein complex or a cell according to the invention.

10 Other characteristics and advantages of the invention appear in the remainder of the description with the examples hereinafter.

### EXAMPLES

15 **EXAMPLE 1:** Construction of an *E. coli* strain including a Cys→Val missense mutation at the thymidylate synthase active site and creating a nutritional requirement for thymine, thymidine or cysteine.

20 The artificial alleles of the *thyA* gene are constructed by site-directed mutagenesis of the plasmid pTS0 (Lemeignan et al. 1993), which derives from the plasmid pTZ18R (BioRad) by insertion of the wild-type *thyA* gene of *E. coli*. The site-directed mutagenesis using an oligonucleotide is carried out according to 25 the method described by Kunkel et al. (1987) on the phagemid pTS0. The preparation of the single-stranded matrix of pTS0, amplified in the strain RZ1032 (Kunkel et al., 1987) (Hfr KL16 P045 [lysA(61-62)] dut1 ung1 thil1 relA1 supE44 zbd-279::Tn10) is carried out 30 according to the protocol described by Sambrook et al. (1989). A 5'-phosphorylated oligonucleotide (purchased from the company Genome Express) is used as a mutagenic primer:

Oligodeoxynucleotide 1:

35 5'PTGGATAAAATGGCGCTGGCACCGGTACATGCATTCTTCCAGTTCTATGT

The hybridization of this oligonucleotide with the single-stranded matrix in each of the two constructions is carried out with 10 ng of oligonucleotide and 0.2 µl of matrix in a volume of

0930669-04001

10  $\mu$ l of a buffer solution containing 20 mM of Tris-HCl, pH 7.5, 2 mM of EDTA and 50 mM of sodium chloride. The tubes are incubated for 5 min at 70°C, and then gradually cooled to 30°C. 0.5 mM of each of the dNTPs, 1 mM of ATP, 10 mM of Tris-HCl at pH 7.5, 10 mM of magnesium chloride, 2 mM of dithiothreitol and 1 unit of each of both the T4 phage DNA ligase and DNA polymerase enzymes are then added to this mixture. This reaction mixture, with a final volume of 20  $\mu$ l, is incubated for 60 min at 37°C, and then 5  $\mu$ l of this are then used to transform competent cells of the *E. coli* K12 strain GT869 (Parsot, C. 1986) (thrB1004 pro thi strA hsdS lacZ  $\Delta$ M15 [F' lacZ  $\Delta$ M15 lacIq traD36 proA+ proB+]) according to the method described by Sambrook et al. (1989). The transformed cells are plated out onto Petri dishes containing LB medium supplemented with 100 mg/l of carbenicillin. Twelve clones resistant to the antibiotic are reisolated on the same medium. The single-stranded DNA corresponding to the phagemids of these clones is prepared and sequenced according to the dideoxy method (Sanger et al., 1977). The M13 sequencing kit (Boehringer Mannheim, Mannheim, Germany) and the deoxyadenosine 5'-( $\alpha$ -thio)triphosphate (1300 Ci/mmol, Amersham) are combined according to the suppliers' indications. Four primers are used to determine the sequence of the thyA alleles:

Oligodeoxynucleotide 3: 5'GGTGTGATCATGATGGTC

Oligodeoxynucleotide 4: 5'CCTGCAAGATGGATTCCC

Oligodeoxynucleotide 5: 5'CGCGCCGCATTATTGTTTC

Oligodeoxynucleotide 6: 5'GTCTGGACCGGTGGCGACA

The plasmid pTS1 thus obtained propagates the thyA:Val146 allele, in which position 146 occupied in the wild-type thyA gene by the UGC codon of cysteine is occupied by the GUA codon of valine. The plasmid pTS1 is introduced by transformation, carried out according to the method of Sambrook et al. (1989), into the *E. coli* K12  $\Delta$ thyA strain,  $\beta$ 1308 (Lemeignan et al., 1993), in which the chromosomal thymidylate synthase gene,

thyA, is deleted. The transformed strain carrying the thyA:Val146 plasmid allele,  $\beta$ 5366, is shown to be incapable of growing without thymine or thymidine being added to the culture medium, as is the strain  $\beta$ 1308 from which it derives. On the other hand, the strain  $\beta$ 5366 shows marginal growth at 30°C on a cysteine diffusion gradient prepared in Petri dishes containing 25 ml of glucose MS mineral medium, starting from a central well containing 0.1 ml of a 400 mM L-cysteine solution. Under the same conditions, the strain  $\beta$ 1308 gives rise to no detectable growth. Thus, the missense mutation which converts the catalytic cysteine at position 146 of thymidylate synthase to valine can be partially suppressed by supplying very large amounts of exogenous cysteine. The addition of 0.1 mM of valine to the medium of the Petri dishes abolishes the growth of the strain  $\beta$ 5366 on a cysteine gradient. Thus, it is as though the cysteine can infiltrate into the valyl-tRNA synthetase active site to form erroneous Cys-tRNAs<sup>Val</sup> capable of correcting the substitution of the cysteine in the thymidylate synthase active site, with valine. The excess of valine would prevent the formation of these erroneous Cys-tRNAs<sup>Val</sup>.

**Example 2:** Construction of an E. coli strain including a Cys→Ile missense mutation at the thymidylate synthase active site and creating a nutritional requirement for thymine, thymidine or cysteine.

The corresponding construction is also carried out in order to replace the cysteine at position 146 of thymidylate synthase, by site-directed mutagenesis using oligonucleotide 2, according to the same protocol as in Example 1.

Oligodeoxynucleotide 2:

5'pTGGATAAAATGGCGCTGGCACCGATACATGCATTCTTCCAGTTCTATGT

The plasmid pTS2 thus obtained propagates the thyA:Ile146 allele in which position 146 occupied in the wild-type thyA gene by the UGC codon of cysteine is

occupied by the AUA codon of isoleucine. The strain which propagates the thyA:Ile146 plasmid allele,  $\beta$ 5274, is shown to require the nutritional supply of thymine, of thymidine or of cysteine in excess, as was the strain  $\beta$ 5366. The phenotypic suppression of the strain  $\beta$ 5274 by the cysteine is abolished with 0.1 mM of isoleucine, as was that of the strain  $\beta$ 5366 with valine. Thus, it is as though the isoleucyl-tRNA synthetase is capable of forming erroneous Cys-tRNAs<sup>Ile</sup> in the presence of an excess of cysteine, and that this erroneous formation is prevented by the presence of an excess of isoleucine.

**Example 3:** Selection of genetic code mutants which misincorporate cysteine instead of valine, by serial culturing in liquid, and genetic characterization of the valyl-tRNA synthetase mutants thus obtained.

The strain  $\beta$ 5366 carrying the thyA:Val146 missense allele on the plasmid pTS1 is cultured in glucose MS mineral medium (2 g/l, Richaud et al., 1993) supplemented with 0.3 mM of thymidine, for 24 h at 30°C in aerobiosis. The cells are then washed twice with deoxygenated MS mineral medium. A deoxygenated nutrient medium containing 10 ml of glucose MS mineral medium supplemented with 1.5 mM of cysteine is inoculated at 1/100 using the washed cells. The cells are then cultured in anaerobiosis for 24 h at 30°C, and a fresh tube containing 10 ml of deoxygenated cysteine glucose MS mineral medium is inoculated with a 1/100 dilution of the previous culture in the stationary phase. This procedure is repeated 26 times. At the end of this serial propagation, 12 clones from the liquid culture are isolated on plates containing thymidine (0.3 mM) glucose (2 g/l) MS mineral medium, in aerobiosis, and stored in suspension in the same liquid medium at -80°C. The twelve clones are tested on plates containing glucose MS mineral medium supplemented with nutrient factors. All these clones are shown to require

thymine or thymidine as a growth factor, unless cysteine is present in the culture medium, at a concentration of at least 1.5 mM.

Two such clones are chosen for a thorough genetic characterization,  $\beta$ 8144 and  $\beta$ 8146. Experiments involving transduction, using the P1 phage, of the kanamycin resistance characteristic, introduced into the *nrdD* locus neighboring the *vals* gene of valyl-tRNA synthetase (97 min of the *E. coli* K12 chromosome), are carried out using the strains  $\beta$ 8144 and  $\beta$ 8146. In both cases, approximately half the kanamycin-resistant transductants also show nutrient dependency for thymidine, which can be suppressed with exogenous cysteine at the concentration of at least 1.5 mM. This proportion is in agreement with the genetic distance between the *vals* and *nrdD* genes (0.4 min) and implies that the phenotype of suppression of the Cys→Val missense mutation at the thymidylate synthase active site with low concentrations of cysteine is caused by the genetic modification of the *vals* locus.

The establishment of a genetic modification in the *vals* gene of the modified strains is confirmed by sequencing this locus: an A changed to a C causes the replacement of the lysine at position 277 with glutamine in the two modified strains  $\beta$ 8144 and  $\beta$ 8146. The sequencing is performed on a matrix obtained via a polymerase chain reaction (PCR) carried out under conditions described by Sambrook et al. (1989). The amplification reaction is carried out in 100  $\mu$ l of a solution containing 10 ng of genomic DNA of the strain  $\beta$ 8144 or  $\beta$ 8146, 20 pmol of each primer, 40 nmol of an equimolar mixture of the 4 deoxynucleotide triphosphates, and 10  $\mu$ l of a buffer composed of 100 mM Tris-HCl pH 8.3, 500 mM KCl and 20 mM MgCl<sub>2</sub>, in the presence of 1 to 2 units of Vent polymerase (Biolabs). For each reaction, 30 polymerization cycles are performed, using a DNA amplifier (Perkin-Elmer Cetus), as follows: the denaturation is carried out at 94°C for 5 min for the 1st cycle and 1 min for the subsequent

0930669 043001



5 Oligodeoxynucleotide 7:  
5'GGGGAATTCGGTGTGTGAAATTGCCGCAGAACG  
Oligodeoxynucleotide 8:  
5'GGCAAGCTTCCAGTATTTACGGGGAGTTATGC

**Example 4:** Phenotypic suppression by metabolic precursors of cysteine.

**Example 5:** Selection of genetic code mutants which misincorporate cysteine instead of valine, by isolation on solid medium, and genetic characterization of the valyl-tRNA synthetase mutants which misincorporate cysteine.

**Example 5:** Selection of genetic code mutants which misincorporate cysteine instead of valine, by isolation on solid medium, and genetic characterization of the valyl-tRNA synthetase mutants which misincorporate cysteine.

The strain  $\beta 5366$  carrying the thyA:Val146 missense allele on the plasmid pTS1 is transduced with a P1 phage lysate harvested on an *E. coli* auxiliary strain ( $\beta 7170$ , Bouzon et al., 1997) into the chromosome of which a kanamycin resistance marker had been introduced at the nrdD locus, neighboring the vals locus of the valyl-tRNA synthetase gene, thus producing the strain  $\beta 5419$ . A mutator allele of the dnaQ gene is introduced extemporaneously by transduction of the strain  $\beta 5419$  using a P1 phage lysate harvested on an auxiliary strain (MS2131, Shapiro 1990) carrying a tetracycline resistance marker dnaQ::miniTn10. Such a tetracycline-resistant clone showing a spontaneous mutation rate amplified approximately 1000-fold (for the acquisition of streptomycin resistance) is cultured at 30°C in glucose minimum medium in the presence of thymidine (0.3 mM). After 24 h, the cells are harvested and washed twice in an identical volume of culture medium without thymidine. A 0.1 ml volume of the resulting suspension, corresponding to approximately  $10^8$  bacteria, is plated out on the surface of a series of Petri dishes containing a concentration of S-carbamyl-L-cysteine ranging between 0 and 8 mM by 1 mM increment, adding the glucose (2 g/l) MS mineral medium. The same procedure is applied to the non-mutator strain  $\beta 5419$ , to the wild-type dnaQ gene. All the Petri dishes are incubated for 96 h at 30°C. Colonies appear on the dishes having a concentration of S-carbamyl-L-cysteine which exceeds 2 mM, only when the dnaQ::miniTn10 mutator allele has been introduced into the strain tested.

A P1 phage lysate harvested from such a clone is used to transduce the strain  $\beta 5366$  carrying the thyA:Val146 plasmid allele. Approximately half the kanamycin-resistant transductants are shown to be capable of growing in the presence of 3 mM of S-carbamyl-L-cysteine and in the absence of thymine or of thymidine, among which transductants, the strain  $\beta 5455$ . The other half of the transductants is incapable of

this and requires thymine or thymidine in order to proliferate, as does the strain  $\beta 5366$ . This proportion between the phenotypes is in agreement with the genetic distance between the *valS* and *nrdD* loci (0.4 min).

5 Thus, the suppression of the Cys $\rightarrow$ Val *thyA* missense mutation with a low concentration of exogenous cysteine might result from modification of the valyl-tRNA synthetase gene. The *valS* locus of one of the strains obtained by transduction of  $\beta 5366$  and capable of  
10 growing in the presence of 3 mM of S-carbamyl-L-cysteine and in the absence of thymine or of thymidine, referred to as  $\beta 5455$ , is amplified by polymerized chain reaction and sequenced as described in Example 3. An A changed to a C causes the replacement of the threonine  
15 at position 222 with proline, thus confirming the establishment of a genetic modification in the *valS* gene of the strain  $\beta 5455$ .

**Example 6:** Sensitivity of the valyl-tRNA  
20 synthetase mutants to noncanonical amino acids.

The strains  $\beta 5455$ ,  $\beta 8144$  and  $\beta 8146$  are tested for their sensitivity to artificial amino acids which show steric resemblance to valine. The test is carried out on dishes containing glucose of MS mineral medium  
25 supplemented with thymidine. The cells are cultured in aerobic medium (glucose MS mineral medium, 0.3 mM thymidine) for 24 h at 30°C and diluted to 1/250 in MS mineral medium. 0.5 ml of this cell suspension is plated out onto Petri dishes containing 25 ml of  
30 glucose MS mineral medium. A well is then hollowed out at the center of the dish and filled with 0.1 ml of an amino acid solution:

- (1) 100 mM L-2-aminobutyrate
- (2) 100 mM L-2-aminovalerate
- 35 (3) 100 mM L-2,3-diaminopropionate
- (4) 50 mM L-3-thiol-2-aminobutyrate.

The dishes are then incubated for 24 h at 30°C and the possible appearance on the dishes of a zone of inhibition around the well is recorded. The diameters

093065-04001  
T00E40-690E860

of the limited zones of growth inhibition on Petri dishes are measured:

L-2-aminobutyrate: 5.2 cm ( $\beta$ 5455), 5.7 cm ( $\beta$ 8144), 6.7 cm ( $\beta$ 8146);

5 L-2-aminovalerate: 2.1 cm ( $\beta$ 5455), 1.5 cm ( $\beta$ 8144), 6.7 cm ( $\beta$ 8146);

L-2,3-diaminopropionate: 2.3 cm ( $\beta$ 5455), 2.7 cm ( $\beta$ 8144), 1.9 cm ( $\beta$ 8146);

10 L-3-thiol-2-aminobutyrate: 2.0 cm ( $\beta$ 5366), 4.6 cm ( $\beta$ 5455), 4.0 cm ( $\beta$ 8144), 4.0 cm ( $\beta$ 8146).

L-2-aminobutyrate, L-2-aminovalerate and L-2,3-diaminopropionate, at the concentrations indicated, have no effect on the strain  $\beta$ 5366 containing the wild-type *valS* allele, but inhibit the growth of the strains carrying a mutated *valS* gene. L-3-thiol-2-aminobutyrate inhibits the growth of all the strains, but a more significant inhibition may be noted on the mutated strains. Thus, it is as though the valyl-tRNA synthetase mutants have a broadened specificity making them capable of charging tRNAs<sup>Val</sup> with amino acids which cannot be incorporated by the wild-type form of the enzyme.

**Example 7:** Incorporation of the noncanonical amino acid  $\alpha$ -aminobutyrate into the proteins of an *E. coli* strain mutated in valyl-tRNA synthetase.

A P1 phage lysate obtained from the strain  $\beta$ 5455 (see Example 5), was used to transduce the strain CU505 carrying an *ÆilvCABD* deletion and a *leu* mutation making it auxotrophic for valine, isoleucine and leucine. The strain CU505 was obtained from the Coli Genetic Stock Center, at Yale University (USA). Transductant clones were selected on kanamycin LB plates and tested for their sensitivity to aminobutyrate (3 mM) in solid glucose (2 g/l) MS medium containing 0.3 mM of each of the three amino acids valine, isoleucine and leucine. Approximately 50% of the transductant clones could not grow under these conditions, indicating the cotransduction of the

vals:T222P allele and the resistance marker nrdD::kan (see Example 5). One of the transductant clones, referred to as  $\beta$ 5498, was used to demonstrate the incorporation of aminobutyrate as a replacement for valine, in comparison with CU505. The two strains were cultured at 30°C in glucose (2 g/l) MS liquid medium containing the Ile-Leu dipeptide at the concentration of 0.3 mM and the Ile-Val dipeptide at the concentration of 0.02 mM, either in the presence of 0.2 mM of L-aminobutyrate or in the absence of the analog. The inoculum corresponding to each strain originated from a preculture in glucose (2 gl) MS liquid medium containing the Ile-Leu dipeptide at the concentration of 0.3 mM and the Ile-Val dipeptide at the concentration of 0.04 mM. The cultures (50 ml) in stationary phase after 24 h at 30°C were harvested by centrifugation. For each test, the pellet was then resuspended in 25 ml of a solution of trichloroacetic acid at 100 g/l (10% TCA) at 4°C, centrifuged, resuspended in 5 ml of 10% TCA, centrifuged again, the pellet resuspended in 5% TCA, the suspension incubated at 95°C for 30 min and centrifuged, the pellet resuspended in 5 ml of acetone and centrifuged, the pellet resuspended in 5 ml of acetone and centrifuged, the pellet resuspended in 5 ml of acetone and centrifuged, and the pellet left to dry. The residue thus obtained was dissolved in 1 ml of a solution of  $\text{NH}_4\text{HCO}_3$  at 50 mM in order to be lyophilized. The lyophilizate was dissolved in 2 ml of 6N hydrochloric acid containing 2 g/l of phenol, and the mixture was sealed in a vial and then incubated at 110°C for 20 h. The amino acid concentration of the hydrolysate was then quantified by derivatization with ninhydrin according to the instructions recommended by the supplier of the Beckman 6300 analyzer. The aminobutyrate was detected in the protein hydrolysate only when the aminobutyrate had been added to the culture medium, and only for the strain  $\beta$ 5498. The aminobutyrate proportion replaced a quarter of the

amount of valine, corresponding to approximately 5 aminobutyrate residues for 100 amino acids of the total proteins. The detailed results of the analyses for the two strains CU505 and  $\beta$ 5498, under the two culture conditions, are given in the table below.

Chemical composition of the proteins extracted from strains auxotrophic for valine and cultured with valine limiting, with or without aminobutyrate

Amino acid	CU505	$\beta$ 5498	CU505	$\beta$ 5498
incorporated into the proteins	wt valS -Abu	valS T222P -Abu	wtvalS +Abu	valS T222P + Abu
Abu	0	0	0	0.20
Val	0.83	0.79	0.83	0.61
Val + Abu	0.83	0.79	0.83	0.81
Ala	1.32	1.28	1.32	1.22
Ile	0.61	0.61	0.61	0.61

Results expressed in Leu equivalents

**Example 8:** Selection of novel genetic code mutants using a mutator strain, for isolation on solid medium.

The strain  $\beta$ 5419, expressing the thyA:Val146 inactive allele on a plasmid and carrying the marker  $\Delta$ nrpD::kan in the chromosome, as reported in the construction thereof described in Example 5, was transduced using a P1 phage lysate harvested on the strain TAD, carrying a mutator marker  $\Delta$ mutS::spc, conferring spectinomycin resistance, selecting on LB solid medium containing spectinomycin (25 mg/l) so as to obtain the strain  $\beta$ 5555. The mutator phenotype of this strain was demonstrated by counting the frequency of rifamycin-resistant mutants. Following the experimental procedure described in Example 5, clones

capable of growing at 30°C in glucose mineral medium without thymidine, in the presence of 2 to 5 mM of S-carbamoyl-L-cysteine (SCC), were obtained. Three of these clones were used to prepare P1 phage lysates which were used to transduce the strain  $\beta$ 5366, selecting for kanamycin resistance, according to the procedure of Example 5. For each of the three lysates, approximately half the transductants were capable of growing in solid glucose mineral medium containing 3 mM of SCC, indicating the proximity of a mutation suppressing the thyA:C146V missense allele and of the marker nrdD::kan. The valS locus of the three strains  $\beta$ 5479,  $\beta$ 5485 and  $\beta$ 5486, each corresponding to an SCC-suppressible transductant obtained from one of the three lysates, was amplified by PCR and sequenced as described in Example 3. A different point mutation was found for each of the three strains, namely Arg 223 changed to His in the strain  $\beta$ 5479, Val 276 changed to Ala in the strain  $\beta$ 5485 and Asp 230 changed to Asn in the strain  $\beta$ 5486. Thus, each clone exhibiting a phenotype of suppression of the Cys 146 Val missense mutant of thyA also exhibits the aminobutyrate sensitivity. Each one of these clones was shown to carry a different point mutation in the valS gene, validating the selective screen as a means of diversifying the activity of valyl-tRNA synthetase in Escherichia coli.

09830669-043001

## BIBLIOGRAPHY

- BAIN J.D., E.S. DIALA, C.G. GLABE, D.A. WACKER, M.H. LYTTLE, T.A. DIX and A.R. CHAMBERLIN, 1991; Site-specific incorporation of nonstructural residues during in vitro protein biosynthesis with semisynthetic aminoacyl-tRNAs, *Biochemistry* 30: 5411-5421.
- BOUZON, M. and P. MARLIERE, 1997; Human deoxycytidine kinase as a conditional mutator in *Escherichia coli*. *C.R. Acad. Sci. Paris* 320: 427-434.
- KUNKEL, T.A., and J.D. ROBERTS, 1987; Rapid and efficient site-specific mutagenesis without phenotypic selection. *Methods Enzymol.* 154: 367-382.
- LEMEIGNAN, B., P. SONIGO and P. MARLIERE, 1993; Phenotypic suppression by incorporation of an alien amino acid. *J. Mol. Biol.* 231: 161-166.
- LEVH, T.F., J.C. TAYLOR and G.D. MARKHAM, 1988; the sulfate activation locus of *Escherichia coli* K12: cloning, genetic, and enzymatic characterisation. *J. Biol. Chem.* 263: 2409-2416.
- PARSOT, C., 1986; Evolution of biosynthetic pathways: a common ancestor for threonine synthase, threonine dehydratase and D-serine dehydratase. *EMBO J.*, 5: 3013-3019.
- RICHAUD, C., D. MENGIN-LECREULX, S. POCHET, E.J. JOHNSON, G.N. COHEN et al., 1993; Directed Evolution of Biosynthetic pathways. *J. Biol. Chem.* 268: 26827-26835.
- SAMBROOK, J., E.F. FRITSCH and T. MANIATIS, 1989; *Molecular cloning: A Laboratory Manual*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
- SANGER, F., S. NICKLEN and A.R. COULSON, 1977; DNA sequencing with chain-terminating inhibitors. *Proc. Natl. Acad. Sci. USA.* 74: 5463-5467.
- SHAPIRO, J.A. 1990; Action of a transposable element in coding sequence fusions. *Genetics* 126: 293-299.

00330669-043001



CLAIMS

1. Method which allows cells to acquire the capacity to produce a protein the amino acid sequence of which comprises at least one unconventional amino acid, characterized in that it comprises the following steps:
- 5 a) transforming said cells by at least one introduction of a missense mutation in a target codon of a gene encoding a protein required for the growth of said cells, said protein synthesized from the gene thus mutated no longer being functional;
- 10 b) where appropriate, culturing the cells obtained in step a) in a culture medium containing a nutrient compensating for the loss of functionality of said protein thus mutated; and
- 15 c) culturing the cells obtained in step a) or b) in a culture medium containing the amino acid encoded by said target codon.
- 20 2. Method according to claim 1, characterized in that the culture medium of step c) does not contain the nutrient required by the loss of functionality of said mutated protein.
3. Method according to either of claims 1 and 2, characterized in that step c) for culturing said cells comprises a series of cultures of said cells in a culture medium containing the amino acid encoded by said target codon, each of said cultures of the series being prepared as far as obtaining the stationary growth phase and followed by washing of the cells obtained, the number of cultures of the series being sufficient to allow the selection of mutations which increase the suppression of said missense mutation of said mutated gene.
- 30 4. Method according to one of claims 1 to 3, characterized in that the missense mutation is chosen from missense mutations which spontaneously reverse
- 35

09370669-043001

only at very low frequency, of the order of one organism from at least  $10^{15}$ .

5. Method according to one of claims 1 to 4, characterized in that the missense mutation transforms a target codon of a gene encoding a protein required for the growth of said cell, into a codon which, in comparison with the target codon, exhibits a change of at least two bases, preferably three bases.

6. Method according to one of claims 1 to 5, characterized in that the target codon encodes an amino acid which has a small steric volume.

7. Method according to one of claims 1 to 6, characterized in that the target codon encodes an amphiphilic amino acid.

8. Method according to one of claims 1 to 7, characterized in that the target codon encodes an amino acid which has a steric volume smaller than or substantially equal to the steric volume of the amino acid encoded by the missense mutation.

9. Method according to one of claims 5 to 8, characterized in that the target codon encodes cysteine.

10. Method according to one of claims 5 to 9, characterized in that the amino acid encoded by the missense mutation is valine or isoleucine.

11. Method according to one of claims 1 to 10, characterized in that step a) for transforming said cells is carried out using a vector comprising a sequence of said gene encoding a protein required for the growth of said cells, including said missense mutation.

12. Method according to claim 11, characterized in that said vector is a plasmid vector.

13. Method for selecting cells capable of producing a protein the amino acid sequence of which comprises at least one unconventional amino acid, characterized in that it comprises steps a), where appropriate b), and c) of a method according to one of claims 1 to 12, and selecting the cells capable of growing in step c).

14. Method for selecting cells according to claim 13, characterized in that it also comprises a step d) for culturing the cells in step c) in a culture medium containing said amino acid encoded by said target codon, the concentration of said amino acid possibly being at a concentration higher than the concentration of said amino acid used in step c), and choosing the cells sensitive to the concentration of said amino acid used in step d).

15. Method for selecting cells according to either of claims 13 and 14, characterized in that the aminoacyl-tRNA synthetase which recognizes the amino acid encoded by said missense mutation of said selected cells is capable of charging onto one of its associated tRNAs an unconventional amino acid or an amino acid other than said amino acid encoded by said missense mutation.

16. Method for selecting cells according to claim 15, characterized in that the nucleic acid sequence of the gene encoding said aminoacyl-tRNA synthetase includes at least one mutation compared with the sequence of the corresponding wild-type gene.

17. Method for selecting cells according to claim 16, characterized in that said mutation has not been introduced by a technique of genetic recombination.

18. Cell obtained using a method according to one of claims 1 to 17.

19. Isolated cell capable of producing a protein the amino acid sequence of which comprises at least one unconventional amino acid, characterized in that it comprises an aminoacyl-tRNA synthetase which recognizes a given amino acid and which is capable of charging onto one of its associated tRNAs an unconventional amino acid or an amino acid other than said given amino acid, and in that the nucleic acid sequence of the gene encoding said aminoacyl-tRNA synthetase includes at least one mutation compared with the sequence of the corresponding wild-type gene, said mutation not having

0930669-043001

been introduced by a technique of genetic recombination.

20. Cell according to claim 18 or 19, characterized in that it is a prokaryotic or eukaryotic cell.

5 21. Cell according to claim 20, characterized in that it is a prokaryotic cell.

22. Cell according to one of claims 18 to 21, characterized in that it is chosen from the following cells deposited at the CNCM (Collection Nationale de Culture de Microorganismes [National Collection of Microorganism Cultures], Paris, France):

- a) *E. coli* strain deposited at the CNCM under the No. I-2025 on May 25, 1998,
- 15 b) *E. coli* strain deposited at the CNCM under the No. I-2026 on May 25, 1998,
- c) *E. coli* strain deposited at the CNCM under the No. I-2027 on May 25, 1998,
- d) *E. coli* strain deposited at the CNCM under the No. I-2339 on October 26, 1999,
- 20 e) *E. coli* strain deposited at the CNCM under the No. I-2340 on October 26, 1999, and
- f) *E. coli* strain deposited at the CNCM under the No. I-2341 on October 26, 1999.

23. Use of a method according to one of claims 1 to 17 for producing protein the amino acid sequence of which comprises at least one unconventional amino acid.

24. Use of a cell according to one of claims 18 to 22 for producing protein the amino acid sequence of which comprises at least one unconventional amino acid.

30 25. Process for producing a protein the amino acid sequence of which comprises at least one unconventional amino acid, characterized in that it comprises the following steps:

- a) where appropriate, selecting a cell by a method according to one of claims 13 to 17;
- 35 b) culturing said cell selected in step a) or a cell according to one of claims 18 to 22 in a culture medium and under culture conditions which allow the growth of said cell; and

00000000 043001

c) isolating said protein comprising at least one unconventional amino acid from the culture supernatant and/or from the cell pellet obtained in step b).

5 26. Process according to claim 25, characterized in that said culture medium of step b) which allows the growth of said cell contains said unconventional amino acid or a precursor thereof.

10 27. Process according to claim 25, characterized in that said unconventional amino acid is synthesized by said cell.

28. Process according to claim 27, characterized in that the synthesis of said unconventional amino acid is increased by genetic modification of said cell.

15 29. Process according to one of claims 25 to 28, characterized in that said cell is auxotrophic for the amino acid encoded by said target codon.


20 30. Process according to one of claims 25 to 29, characterized in that said cell comprises a homologous or heterologous gene of interest the coding sequence of which includes at least one target codon.

25 31. Process according to claim 30, characterized in that step b) comprises the compounds required for inducing the synthesis of the protein encoded by said gene of interest.

30 32. Process according to claim 30 or 31, characterized in that the biological activity of the protein encoded by said gene of interest is at least partially conserved after the incorporation of said unconventional amino acid at the level of the target codon of said gene of interest.

35 33. Process according to one of claims 25 to 32, characterized in that the unconventional amino acid is chosen from unconventional amino acids of formula I of configuration L

09330669 043001



(I)

in which:

R<sub>1</sub> or R<sub>2</sub> represents radicals containing a functional  
5 group capable of reacting selectively.

34. Process according to claim 33, characterized in  
that the functional group is chosen from aldehyde,  
ketone, ethenyl, ethynyl and nitrile groups.

35. Process according to one of claims 25 to 34,  
10 for protein functionalization.

36. Protein purification process, characterized in  
that it comprises the following steps:

a) incorporating into the amino acid sequence of said  
protein an unconventional amino acid containing a  
functional group capable of reacting selectively,  
15 using a process according to one of claims 25 to  
35;

b) bringing the solution containing the protein  
obtained in step a) into contact with a support  
comprising a compound capable of reacting  
specifically with said functional group and of  
20 attaching specifically said protein; and

c) isolating said protein attached to the support.

37. Process for attaching a protein to a chemical  
25 or biochemical compound, characterized in that it  
comprises the following steps:

a) incorporating into the amino acid sequence of said  
protein, by a process according to one of claims  
25 to 35, an unconventional amino acid containing  
30 a functional group capable of reacting  
selectively;

b) bringing the protein obtained in step a) into  
contact with said chemical or biochemical compound  
comprising a group capable of reacting

09030669, 043001

38. Process according to claim 37, characterized in that said chemical or biochemical compound is, itself, attached to a solid support or is a constituent compound of a solid support.

40. Process according to claim 39, characterized in  
10 that the attached protein or the chemical or  
biochemical compound is chosen from therapeutic,  
cosmetic or diagnostic compounds.

42. Process according to claim 39 or 40,  
characterized in that the chemical or biochemical  
compound is chosen from compounds the biological  
20 activity of which can be modified by the attached  
protein.

44. Protein obtained using a process according to one of claims 25 to 36.

46. Protein complex obtained using a process according to one of claims 39 to 43.

48. Diagnostic process, characterized in that it uses a protein according to claim 44 or 45, or a protein complex according to claim 46.

## ABSTRACT

The invention concerns processes enabling prokaryotic or eukaryotic cells to acquire the capacity to produce proteins whereof the amino acid sequences comprise at least a non-standard amino acid, methods for selecting said cells, methods for producing and purifying said proteins and cells and proteins obtained by said methods and processes. The invention also concerns uses of said cells and proteins in various fields such as therapeutics, cosmetics, diagnosis or biosynthesis or biodegradation of organic compound

T.O.E.H. 6990E869 09830669 043001



# Declaration, Power Of Attorney and Petition

Page 1 of 3

WE (I) the undersigned inventor(s), hereby declare(s) that:

My residence, post office address and citizenship are as stated below next to my name,

We (I) believe that we are (I am) the original, first, and joint (sole) inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled

Process for producing chemically diversified proteins, in vivo, by incorporating  
unconventional amino acids

the specification of which

☐ is attached hereto.

☐ was filed on \_\_\_\_\_ as

Application Serial No. \_\_\_\_\_

and amended on \_\_\_\_\_.

☒ was filed as PCT international application

Number PCT/FR99/02628

on October 28, 1999,

and was amended under PCT Article 19

on \_\_\_\_\_ (if applicable).

We (I) hereby state that we (I) have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

We (I) acknowledge the duty to disclose information material to the examination of this application in accordance with Section 1.56(a) of Title 37 Code of Federal Regulations.

We (I) hereby claim foreign priority benefits under Section 119 of Title 35 United States Code, of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Application No.	Country	Day/Month/Year	Priority Claimed
<u>98/13533</u>	<u>FRANCE</u>	<u>28 October 1998</u>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No


We (I) hereby claim the benefit under Section 120 of Title 35 United States Code, of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Section 112 of Title 35 United States Code, We (I) acknowledge the duty to disclose material information as defined in Section 1.56(a) of Title 37 Code of Federal Regulations, which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial No.	Filing Date	Status (pending, patented, abandoned)
_____	_____	_____
_____	_____	_____
_____	_____	_____

And we (I) hereby appoint: Norman F. Oblon, Registration Number 24,618; Marvin J. Spivak, Registration Number 24,913; C. Irvin McClelland, Registration Number 21,124; Gregory J. Maier, Registration Number 25,599; Arthur I. Neustadt, Registration Number 24,854; Robert C. Miller, Registration Number 25,357; Richard D. Kelly, Registration Number 27,757; James D. Hamilton, Registration Number 28,421; Eckhard H. Kuesters, Registration Number 28,870; Robert T. Pous, Registration Number 29,099; Charles L. Gholz, Registration Number 26,395; Vincent J. Sunderdick, Registration Number 29,004; William E. Beaumont, Registration Number 30,996; Steven B. Kelber, Registration Number 30,073; Stuart D. Dwork, Registration Number 31,103; Robert F. Gnuse, Registration Number 27,295; and Jean-Paul Lavalleye, Registration Number 31,451, our (my) attorneys, with full powers of substitution and revocation, to prosecute this application and to transact all business in the Patent Office connected therewith; and we (I) hereby request that all correspondence regarding this application be sent to the firm of OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C., whose Post Office Address is: Fourth Floor, 1755 Jefferson Davis Highway, Arlington, Virginia 22202.

We (I) declare that all statements made herein of our (my) own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

MARLIERE, Philippe  
NAME OF FIRST SOLE INVENTOR

  
Signature of Inventor

Date

16.03.2001

Residence: 2, allée Saint-Martin  
91450 ETIOLLES / FR FRX  
Citizenship: French  
Post Office Address: the same as the Residence

200 DÖRING, Volker

NAME OF SECOND JOINT INVENTOR

Signature of Inventor

*Volker Döring*

Date

16.03.2001

NAME OF THIRD JOINT INVENTOR

MOOTZ, Heinning

Signature of Inventor

Date

NAME OF FOURTH JOINT INVENTOR

Signature of Inventor

Date

NAME OF FIFTH JOINT INVENTOR

Signature of Inventor

Date

Residence: 31, rue St. Amand

75015 PARIS / FR

Citizenship: French

Post Office Address: the same as the  
residence

Residence: Ziegelstrasse 11

35037 MARBURG / DE

Citizenship: German

Post Office Address: the same as the  
residence

Residence:

Citizenship:

Post Office Address:

Residence:

Citizenship:

Post Office Address:

DÖRING, Volker

NAME OF SECOND JOINT INVENTOR

Signature of Inventor

*Volker Döring*

Date

NAME OF THIRD JOINT INVENTOR

MOOTZ, Heinning

Signature of Inventor

*Heinning Mootz*

Date

16.03.2001

NAME OF FOURTH JOINT INVENTOR

Signature of Inventor

Date

NAME OF FIFTH JOINT INVENTOR

Signature of Inventor

Date

Residence: 31, rue St. Amand

75015 PARIS / FR

Citizenship: French

Post Office Address: the same as the  
residence

Residence: Ziegelstrasse 11

35037 MARBURG / DE

DEX

Citizenship: German

Post Office Address: the same as the  
residence

Residence:

Citizenship:

Post Office Address:

Residence:

Citizenship:

Post Office Address: